Austin, United States
Maxwell Biosciences, founded in 2016 and headquartered in the United States, is making significant strides in the biopharmaceutical industry with its innovative 'Next Generation Anti-Infectives' platform. The company aims to revolutionize antiviral and antimicrobial treatments by developing low molecular weight drug candidates that mimic natural human peptides, targeting a range of threats from SARS-CoV-2 to bacterial and fungal pathogens.
Fueled by over $35 million in non-dilutive grants, Maxwell's research is reinforced by independent studies showcasing its drug candidates' direct virucidal activity and unique tissue-safe toxicology profile. The first-in-class CLAROMER™ drug discovery platform is key to this progress, offering promising solutions to emergent viral pandemics and evolving infectious pathogens.
Having recently secured a $20.00 million early VC investment, Maxwell is poised for further growth, focusing on advanced preclinical and human trials, marking a compelling opportunity for investors committed to transformative healthcare solutions.
